Frontage is a global CRO advancing drug discovery and development with a comprehensive portfolio of genomics services. We deliver accurate and in-depth analyses to move compounds through early discovery and preclinical studies and for translational and clinical programs.
Register to gain access to gated resources.
Thank you for registering!
You now have the option of downloading the resource or viewing the web version below.
Liquid biopsy is a sampling method for biomarker analysis that minimizes invasiveness, allows routine sampling, and is associated with circulating cell-free DNA. In this webinar, we talk about the benefits and challenges of sequencing cell-free DNA.
Sequencing the bacterial 16S rRNA gene is an established technique for assessing the phylogenetic diversity of microbial communities. This white paper discusses the methods and process to elucidate that Frontage’s QIIME2 analysis pipeline accurately estimates the composition of microbiome samples, as shown by the similarity to the theoretical abundance.
Frontage has developed a next-generation sequencing (NGS)-based method to rapidly determine the genotype of 300+ genes involved in ADME, called the Frontage PGx NGS Test.